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Luke’s Hospital, Milwaukee, Wisconsin

We dedicate this report to Sandy Petersdorff and the other staff in
Computer Services. Sandy has been the liaison to the Cancer Registry
for several years and her enthusiasm and support have been greatly
appreciated. We also wish to acknowledge the people in her department
for their assistance with our computerized registry.
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CANCER PROGRAM ACTIVITY REPORT
at St.
During 1984 there has been continued growth and development of cancer care
review of
Luke’s Hospital. The Cancer Committee has provided a forum for critical
education and
these changes in diagnostic approach, treatment facilities, research,
rehabilitation.
staging system
The Cancer Committee has encouraged widespread use of the TNM
facilitate this critical
in the hospital and has developed a staging work sheet to
cancer care
component of patient management. A mechanism to assess the quality of
manag
ement of
in our hospital has been introduced. This will initially evaluate the
scope will be
breast cancer and pancreatic cancer but with further experience its
participation in a
increased to include all malignancies. This year the hospital began
define the
National Cancer Institute sponsored Pattern of Care Study, designed to
the US.
quantity and quality of cancer care in community-based facilities across
Hospital remains
The number of patients diagnosed with cancer per year at St. Luke’s
reported in the
high. New cases identified in 1983 represented nearly 6% of all cases
statistics and has
state. Each year the Cancer Registry has monitored cancer patient
in-dep
th study of
prepared comprehensive reports. This year’s report includes an
characterprostatic cancer, and involves 50 patients. The study highlights well-known
and manageistics of this common disease. The disease frequency increases with age,
degenerative
ment is often complicated by the coexistence of cardiovascular and
diagnosis was
diseases. No exogenous etiologic factors could be identified. The
grading
established by biopsy in all patients and clinical studies allowed staging and
patient
s had
classification in almost all patients. Although a significant proportion of
utilized RadIation
Ii m ited extent d isease at d iagnosis, rad ical prostatectOmy was not
managed with
therapy was delivered in one-fifth of the patients. The majority were
with a low
palliative surgery and hormonal manipulation. Treatment was associated
alive and onerate of complications. Half of the patients in the long-term study are
Luke’s
quarter are free of signs of their disease. This analysis of prostatic cancer at St.
Hospital can serve as a basis for future treatment planning and study.
patients with cancer.
We have enjoyed a year of rapid expansion in our ability to care for
facilities
A high energy radiation therapy unit has been added, inpatient oncology
support
have been expanded and improvements have continued in rehabilitation,
surgical,
services, pharmacy and diagnostic capabilities. This has attracted additional
facilita
ted
medical and radiation oncologists to the program who together have
forward to
delivery of the highest quality of cancer care to all our patients. We look
further expansion of activities in the year ahead.
.

Ronald D. Hart, M.D.
Chairman, Cancer Committee
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1983 NEW CANCER CASES AT ST. LUKE’S

Male

Female

Male

Female

115

45

28

(3%)

Leukemia

21

7

1

99

28

(3°h)

Bladder

21

7

160

(19%)

Lung

100

(12°h)

Breast

88

Skin

44

44

25

(3°h)

Kidney

16

9

83

(1O°h)
(10%)

Colon

51

32

24

(3%)

Stomach

15

9

58

(7°h)

Prostate

58

19

(2%)

Larynx

17

2

37

(4°h)

Rectum

22

15

181

(21°h)

Other Sites

30

(3°h)

Unknown
Primary

13

17

861

TOTAL

1983 NEW CANCER CASES IN WISCONSIN
2,187 (14%) Breast
1,958 (1 3%) Trachea, Bronchus, Lung
1,735 (11%) Colon
1,617 (11%) Prostate
735

(5%)

Urinary Bladder

725

(5%)

Rectum, Rectosigmoid Junction,
and Anus

698

(5%)

Cervix Uteri

557

(4%)

Corpus Uteri

5,114 (32%) Other Sites

15,326

TOTAL CASES REPORTED

*

*A5 of 7/25/84.
Information from Wisconsin
Bureau of Health Statistics.
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PROSTATE CANCER STUDY
A long and short-term study of cancer of the prostate was conducted by
St. Luke’s Hospital Cancer Registry as part of a nation-wide study by the
American College of Surgeons. The goal of the long-term study was to
compare the frequency of occurrence and survival of prostate cancer
patients. A total of 25 patients diagnosed here in 1978 had their records
abstracted for th is study.
Likewise, 25 patient records were abstracted for the short-term study.
Patients diagnosed in 1983 were included in the short-term study. The
main purpose of the short-term study was to compare the patterns of
diagnosis and treatment for prostate cancer patients.
According to national statistics from the American Cancer Society, there
are approximately 73,000 new prostate cancer cases diagnosed each year.
Cancer of the prostate is one of the most common cancers in men over the
age of 50 and the third leading cause of male deaths from cancer, with
the median age being 70 years old.

AGE AT DIAGNOSIS

NUMBER
OF
CASES

12
11
10
9
8
7
6
5
4
3
2
1
0
40-49

50-59

60-69

70-79

80-89

AGE DISTRIBUTION IN DECADES
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SYMPTOMS
Since cancer of the prostate is a relatively slow-growing cancer, it may not
be deteãted until other diseases bring the patient in to seek medical
assistance. Six of the 25 patients in the short-term study had admission
diagnoses that were not related to cancer of the prostate. Nineteen of the
25 patients in the short-term study presented with some symptoms of
1ancer of the prostate. The most common symptom was frequent micturi
tion, 44°k of the patients presented with this symptom. Other common
symptoms included hesitancy, decrease in stream, and complete retention.
Least common symptoms included hematuria, urinary pain, weight loss,
and bone pain.

DIAGNOSTIC LAB TESTS AND X-RAYS
Of the lab tests and x-rays done to aid in establishing a diagnosis in the
long and short-term studies, both had 100% compliance with chest x-rays
being done. In both studies, 8% had positive findings on the chest x-ray.
There was also a 24% increase in the ordering of acid phosphatase at
work-up between 1978 and 1983.

COMPARISON: LAB VALUES

Alkaline
Phosphatase

Acid
Phosphatase
1978

1983

60%

84%

%

44%

56%

16%

28%

Done
%

100%

100%

56%

64%

48%

36%

Normal

Normal

Elevated

1983

%

%
Done

%

1978

%
Elevated
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STAGE AT THE TIME OF DIAGNOSIS
Staging of prostate cancer has traditionally been on a clinical basis, usually
not considering lymph node involvementorthe histopathologic grade of the
cancer. Although, only about half of all nodules palpable by rectal exam are
cancerous, 85% of all prostate cancers start in the posterior lobe
of the prostate which is within easy reach during the rectal exam.
Staging by the American Urologic system is an A-B-C-D system that has
been adaptedtotheTNM (T-primarytumor; N-nodal involvement; M-distant
metastases) system The followi ng d iag ram and cli n ical stag i ng system will
explain staging as it was applied to this study.
.

D 1D2

C

B

A

(çs
T3

12

14

/jtN

M+

PR/1i 2

(Diagram from Clinical Oncology: A Multidisciplinary Approach.)
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Stage A-i

-

Microscopic focus of well-differentiated adenocarcinoma in 3
or Iessfoci ofthe prostatespecimen. Negative rectalexam, acid
phosphatase normal, normal bone scan
AJCC Stage ha, NO, MO

Stage A-2

Tumor not well differentiated or greater than 3 foci of tumor
Negative rectal exam, acid phosphatase normal, negative
bone scan
AJCC Stage TIb, NO, MO

Stage B-i

Nodule equal to or greater than i.5 to 2 centimeters on
rectal exam
Acid phosphatase normal, normal bone scan
AJCC Stage T2a, NO, MO

Stage B-2

Diffuse involvement of the gland but no capsular extension
on rectal examination.
Acid phosphatase normal, normal bone scan
AJCC Stage T2b, NO, MO

Stage C-i

No involvement of seminal vesicles, less than 70 grams
Acid phosphatase normal or elevated, normal bone scan
AJCC Stage T3a, NO, MO

Stage 0-2

More than 70 grams, or involving the bladder neck, trigone,
or seminal vesicles.
Acid phosphatase normal or elevated, normal bone scan
AJCC Stage T3b, NO, MO or T4, NO, MO

Stage D-i

Primary of any size with metastases to pelvic lymph nodes
below the aortic bifurcation
Acid phosphatase normal or elevated, normal bone scan
AJCC Stage Any T, Nl-2, MO

Stage D-2

Any size of primary with lymph node metastases above the
aortic bifurcation or other soft tissue metastases or bone
m etastases
Acid phosphatase normal or elevated, normal or positive
bone scan
AJCC Stage Any T, Any N, Ml
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In the long-term study, 5 patients had Stage A-i disease and 4 had A-2 for a
total of 9 patients with occult-incidental disease. A total of 1 i patients had
Stage B disease with 2 of these substaged as B-2. One patient had Stage
C-2 disease, and 4 patients had distant disease with 3 of the 4 patients
having metastases to bone. One patient had lymph node involvement
besides bone metastases. One patient had metastases to the
lungs.
The short-term study is comparable to the long-term study in terms of
staging. Eleven patients had Stage A-i disease, 1 had B-i, 6 had B-2,
i had C-i and 6 had D-2. All patients having Stage D-2 disease had
metastases to the bone.

HISTOPATHOLOGY
Cancer of the prostate is almost always an adenocarcinoma, which supports
our data for both the long-term and the short-term studies. In both the
long-term and short-term studies, 24 of the 25 cases were adenocarcinomas
and one was listed as carcinoma, not otherwise specified.
The traditional grading of well, moderately, and poorly differentiated has
been shown to correlate with the patients’ survival and the metastatic
potential of the cancer. We found a substantial difference between the
long-term study and the short-term study concerning differentiation.
The majority of patients in the long-term group had well differentiated
tumors, whereas most in the short-term group had moderately or poorly
differentiated cancers.
PATHOLOGICAL DIFFERENTIATION

Well
Diff.

Mod.
Diff.

Poor
Diff.

Not
Graded

Total

1978:

19

5

0

1

25

1983:

8

11

6

0

25
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GLEASON SCORE
We were able to collect the Gleason score on most patients in the 1983
study, but since this system was not in use in earlier years there were no
Gleason scores available from the 1 978 study. The Gleason score considers
the grade of the tumor along with the growth pattern of the cancer in
relationship to the prostate gland.
This system assigns a histologic grade to the primary pattern of the
cancer and to the secondary pattern of the cancer. These two scores are
then added together to obtain the Gleason score. If there is no secondary
pattern, the two primary pattern scores are added together to determine
the Gleason score. The Gleason score can range from 2-10, the higher the
Gleason score, the worse the prognosis.
The most common Gleason score, where reported, was 6, with scores
ranging from 2-7. In three cases, there was no Gleason score obtainable
due to the nature of the specimen, and in one case a biopsy of the bone
established the diagnosis and no tissue from the prostate was obtained.

GLEASON SCORE: SHORT-TERM STUDY (1983)

9
8
7
NUMBER
OF
PATI ENTS

6
5
4
3
2
1
0
2

3

4

5

GLEASON SCORE
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MODES OF DIAGNOSIS
The most common mode of diagnosis in both the long-term and short-term
stud ies was a TU R P (trans u reth ral resecti o n of the p rostate) So me
patients had more than one mode of diagnosis such as a TURP and a
clinical diagnosis by rectal exam orTURP and a needle biopsy. Other modes
of diagnosis included a needle biopsy of the pubic bone and lumbosacral
lam i nectomy.
.

Transrectal
Biopsy

mm

Needle
Aspiration
Biopsy

—

1983
1978

Cytology
.

Incidental
Finding at
Prostatectomy

Clinical dx.
with bone lesion
Perineal
Biopsy

111111
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Clinical dx.
lllIlllllIlIllllllllllllIlllIllllllIlllIllllIlllIlHHIIIIl
by Rectal Exam
Transu rethral
Resection of
Prostate

Li

2

3

4

5

6

7

8

91011121314151617181920

# OF EACH
TYPE OF DIAGNOSIS

10

TREATMENT
The most common mode of treatment in both the long and short-term
studies was a TURP. Hormones have been used fairly constantly in both
studies with the difference being an increase in the dosage in the short-term
study (1983) to 2 and 3 milligrams of DES as compared to 1 milligram
dosages in the long-term study (1978).

TREATMENT
TRANSURETHRAL

1978

1983

RESECTION OF PROSTATE
(TURP)

6 (24%)

1 1 (44%)

TURP AND HORMONES

8 (32%)

6 (24%)

TURP AND RADIATION

5 (20%)

2 (8%)

HORMONES ONLY

2 (8%)

1 (4%)

RADIATION ONLY

1 (4%)

2 (8%)

OTHER

3 (12%)

3 (12%)

25 (100%)

25 (100%)
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COMPLICATIONS: SHORT-TERM STUDY
(1983)
ComplicatiOnS were very few, occurring in 4 patients in the short-term
study. Complications included:
2 patients with urinary complications
1 patient with non-cardiac related chest
pain and increased abdominal discomfort
1 patient with cardiac complications
All complications were resolved by the time of discharge.
Data regarding complications was not collected in the long-term study.

LENGTH OF STAY: SHORT-TERM STUDY
(1983)
The overall length of stay in the short-term study varied widely from
a 2-day stay up to a 20-day stay. The average overall length of stay was 10.5
days. If the lengths of stay for patients admitted for a diagnosis unrelated to
cancer are eliminated from the average length of stay, the average length of
stay goes down almost a full day to 9.6 days. Stage did not appear to
influence length of stay.

SURVIVAL STATUS: LONG-TERM STUDY
(1978 DIAGNOSES)
At the time of this study, 1984, 12 of the 25 patients were alive; 6 of these
patients had evidence of disease and 6 patients were free of
disease. Of the 6 patients who were alive with no evidence of disease, 4
patients had Stage A disease and 2 had Stage B disease. Thirteen patients
had died, 8 with evidence of disease, 2 with no evidence of disease, and 3
with an unknown cancer status at the time of death. Of the patients that had
died with disease, 5 had Stage B disease, 2 had Stage D disease, and one had
Stage A disease. Of the two patients that are dead with no evidence of disease,
one patient had Stage B disease and the other patient had Stage D disease.
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